Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA)

Peter R. Rehani, Hanaa Iftikhar, Motowo Nakajima, Tohru Tanaka, Zaid Jabbar, Riyadh N. Rehani

doi:10.1155/2019/4267357

Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA)

DOI PDF XML 被引用文献3件

Peter R. Rehani

University of Wisconsin-Madison, Madison WI, USA
Hanaa Iftikhar

Royal College of Surgeons in Ireland, Bahrain
Motowo Nakajima

SBI Pharmaceuticals Co. Ltd., Tokyo, Japan
Tohru Tanaka

SBI Pharmaceuticals Co. Ltd., Tokyo, Japan
Zaid Jabbar

DuPage Medical Group, Chicago, IL, USA
Riyadh N. Rehani

SBI ALApharma Co. Ltd., Hong Kong

書誌事項

公開日: 2019-11-06

権利情報

http://creativecommons.org/licenses/by/4.0/

DOI

10.1155/2019/4267357

公開者: Wiley

この論文をさがす

CiNii Books

説明

<jats:p>5-Aminolevulinic acid (5-ALA) is a delta amino acid naturally present in every living cell of the human body. 5-ALA is produced in the mitochondria as the first product of the porphyrin synthesis pathway and composes heme; exogenously supplemented 5-ALA helps in upregulating mitochondrial functions. Mitochondrial dysfunction has been associated with the pathophysiology of diabetes mellitus. Thus, in this review, we evaluate the mechanisms of action and adverse effects of common medications used to treat type 2 diabetes mellitus as well as 5-ALA including its mechanism and possible use in diabetes management.</jats:p>